Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | YAP1 | P46937 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518834 | 0.92 | CYSLTR2 (0.46) | CYSLTR2POLBMEN1KMT2ALTA4H | |
| SCHEMBL4517382 | 0.91 | TSHR (0.41) | CYSLTR2RECQLTSHRYAP1NPC1 | |
| SCHEMBL13918480 | 0.91 | CYSLTR2 (0.46) | CYSLTR2TSHRNPC1ALDH1A1RAB9A | |
| SCHEMBL4516413 | 0.85 | CYSLTR2 (0.56) | CYSLTR2RECQLYAP1NPC1HPGD | |
| SCHEMBL13918518 | 0.83 | TSHR (0.56) | CYSLTR2TSHRNPC1ALDH1A1RAB9A | |
| SCHEMBL4526325 | 0.82 | CYSLTR2 (0.49) | CYSLTR2TSHRNPC1ALDH1A1RAB9A | |
| SCHEMBL4510798 | 0.81 | CYSLTR2 (0.53) | CYSLTR2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL13918237 | 0.81 | MAPT (0.50) | RECQLTSHRNPC1ALDH1A1RAB9A | |
| SCHEMBL4516364 | 0.80 | CYSLTR2 (0.53) | CYSLTR2RECQLTSHRNPC1ALDH1A1 | |
| SCHEMBL4522253 | 0.80 | CYSLTR2 (0.64) | CYSLTR2RECQLNPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | CYSLTR2 1426/4885RECQL 2021/4885TSHR 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.